INTERFERON AND RIBAVIRIN-FREE THERAPY WITH SOFOSBUVIR AND DACLATASVIR IN A REAL-LIFE COHORT OF DIFFICULT-TO-TREAT HIV/HCV-COINFECTED PATIENTS WITH AND WITHOUT PORTAL HYPERTENSION

Conference Reports for NATAP

EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria april 22-26


INTERFERON AND RIBAVIRIN-FREE THERAPY WITH SOFOSBUVIR AND DACLATASVIR IN A REAL-LIFE COHORT OF DIFFICULT-TO-TREAT HIV/HCV-COINFECTED PATIENTS WITH AND WITHOUT PORTAL HYPERTENSION

	Reported by Jules Levin EASL April 22-26 2015 Dr. Mattias Mandorfer Austria EASL: Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension - (04/29/15)